- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00058773
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (ANGELA)
Administration of Autologous Neomycin Resistant Gene Marked EBV Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving Autologous Bone Marrow Transplant for Relapsed EBV-Positive Lymphoma.
Subjects have a type of lymph gland cancer called Hodgkin or non-Hodgkin Lymphoma, which has come back or not gone away after treatment, including the best treatment we know for relapsed Lymphoma. We are asking subjects to volunteer to be in a research study using Epstein Barr virus (EBV) specific cytotoxic T lymphocytes, a new experimental therapy. This therapy has never been used in patients with Hodgkin disease or this type of non-Hodgkin Lymphoma but it has been used successfully in children with other types of blood cancer caused by EBV after bone marrow transplantation.
Some patients with Hodgkin disease or non-Hodgkin Lymphoma show evidence of infection with the virus that causes infectious mononucleosis Epstein Barr virus (EBV) before or at the time of their diagnosis of Lymphoma. EBV is often found in the cancer cells suggesting that it may play a role in causing Lymphoma. The cancer cells infected by EBV are very clever because they are able to hide from the body's immune system and escape destruction. We want to see if we can grow special white blood cells, called T cells, that have been trained to kill EBV infected cells and give them back to subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We will take 60-70 ml (12 teaspoonfuls) of blood from the subject. We will first make a B cell line called a lymphoblastoid cell line or LCL by infecting the subjects blood with a laboratory strain of EBV called B95. We will then use use this EBV infected cell line (which have been treated with radiation so that they cannot grow) as stimulator cells and mix it with more blood. This stimulation will train the T cells to kill EBV infected cells and result in the growth of an EBV specific T cell line. We will then test the T cells to make sure that they kill the EBV infected cells and not your normal cells and freeze them.
The cells will be thawed and injected into subjects over 10 minutes, after pretreatment with Tylenol and Benadryl. A total of two doses will be given two weeks apart. All of the treatments will be given at Texas Children's Hospital or The Methodist Hospital.
We will follow subjects in the clinic after the injections. At each visit about 10ml (2 teaspoonfuls) of blood will be taken every other week for 6 weeks after the injection and then every 3 months for 1 year to monitor the subjects blood chemistry and hematology.
To learn more about the way the T cells are working in the subjects body, an extra 40mls (8 teaspoons) of blood will be taken pre-infusion, 3-4 days post infusion (optional) and at 1, 2, 4 and 6 weeks post-infusion and then at 3, 6, 9, and 12 months. The blood may be drawn from the subjects central line at the time of their regular blood tests.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Any patient with Hodgkin disease or non-Hodgkin Lymphoma, containing the EBV genome or antigen, receiving an autologous bone marrow transplant regardless of age or sex.
- Patients with tumor tissue EBV +ve.
- Patients with life expectancy >6 weeks.
- Patients with Karnofsky score of > 50.
- No severe intercurrent infection.
- Patient, parent/guardian able to give informed consent.
- Patient with Bilirubin <2x normal, SGOT <3x normal, and ANC greater than 500mm
- Patients with creatinine <2x normal for age or creatinine clearance >2x normal for age.
- Patients should have been off other investigational therapy for one month prior to entry in this study.
EXCLUSION CRITERIA:
- Patients with a life expectancy of <6 weeks.
- Patients with an EBV positive Lymphoma secondary to an acquired or congenital immunodeficiency.
- Patients with a Karnofsky score less than or equal to 50.
- Patients with a severe intercurrent infection.
- Patients with a bilirubin >2x normal,SGOT >3x normal, or abnormal prothrombin time.
- Patients with a creatinine >2x normal for age or creatinine clearance <2x normal for age.
- Patients with an ANC <500mm
- Patient, parent/guardian unable to give informed consent.
- Patients who have been on other investigational therapy within one month prior to entry in this study.
- Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. Women of childbearing potential must be on appropriate birth control for the duration of the study and 6 months after completion of the study. In addition, the male partner should use a condom.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CTL Administration
Infusion of EBV Specific Cytotoxic T-Lymphocytes
|
EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes. Each patient will receive two injections, 14 days apart. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
determine the safety of 2 IV injections of autologously derived EBV specific cytotoxic T-lymphocytes
Time Frame: 8 weeks
|
The two injections will be given at day 0 and day 14.
Three patients will be enrolled at the first dose level and followed for six weeks after the second dose (which will constitute a course) for evaluation of any critical toxicity.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
determine the survival, immunological efficacy and anti-tumor effects of EBV specific cytotoxic T-lymphocyte lines.
Time Frame: 1 year
|
During the course of the study the survival, immunological efficacy and anti-tumor activity of neomycin resistance gene marked EBV specific cytotoxic T-lymphocyte lines will also be studied.
In order to get a reasonable insight into the anti-tumor activity and late toxicity the patients will be followed for additional six weeks.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Catherine Bollard, MD, Baylor College of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-6422-ANGELA
- ANGELA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin Disease
-
Tessa TherapeuticsActive, not recruitingHodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, PediatricUnited States
-
Tessa TherapeuticsBristol-Myers SquibbActive, not recruitingClassical Hodgkin Lymphoma | Hodgkin Disease Recurrent | Hodgkin Disease RefractoryUnited States
-
Shandong Provincial HospitalUnknownLymphoma, Non-Hodgkin;Hodgkin DiseaseChina
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
AkesoPeking University Cancer Hospital & InstituteRecruiting
-
Stanford UniversityCompletedLymphoma | Hodgkin Disease | Lymphoma, Hodgkin Disease | Lymphoma: HodgkinUnited States
-
Grupo Argentino de Tratamiento de la Leucemia AgudaTakedaRecruitingRefractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, AdultArgentina
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, France, Canada, Belgium, Italy
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedDisease, HodgkinUnited States, Canada
Clinical Trials on Infusion of EBV Specific Cytotoxic T-Lymphocytes
-
Sumithira VasuRecruitingCytomegalovirus | Adenovirus | Donor | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Solid Organ Transplantation RecipientUnited States
-
Beijing Friendship HospitalRecruitingChronic Active Epstein-Barr Virus Infection | Virus-Associated Hemophagocytic SyndromeChina
-
Baylor College of MedicineThe Methodist Hospital Research InstituteTerminatedNon-Hodgkin Lymphoma | Hodgkins LymphomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Milton S. Hershey Medical CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cytomegaloviral InfectionUnited States
-
New York Medical CollegeJohns Hopkins University; University of Colorado, Denver; Children's Hospital... and other collaboratorsRecruitingPrimary Immune Deficiency Disorder | AdenovirusUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...TerminatedBrain Cancer | Glioblastoma Multiforme | GBMUnited States
-
New York Medical CollegeJohns Hopkins University; Children's Hospital of Philadelphia; Washington University... and other collaboratorsRecruitingPrimary Immune Deficiency Disorder | Cytomegalovirus InfectionsUnited States